UniQure to Seek FDA Approval for Huntington's Gene Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: CNBC
- New FDA Guidance: UniQure learned in a recent meeting that a three-year analysis from a Phase 1/2 study would support accelerated approval for its Huntington's disease gene therapy, marking a significant turnaround after previous criticisms.
- Clinical Data Reversal: Although the FDA previously indicated that UniQure's clinical trial data was insufficient for application support, the new guidance reflects a shift in FDA policy, potentially bringing renewed hope for rare disease drug development.
- Strong Market Reaction: Following the announcement, UniQure's shares surged 70%, indicating investor optimism about the company's future prospects, especially with FDA backing, which could rapidly increase demand for its gene therapy.
- Commitment to Further Research: UniQure has pledged to align with the FDA on study design before submitting its application, including comparing the treatment to current standard care, ensuring the therapy's efficacy and laying the groundwork for future market introduction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 48.160
Low
33.00
Averages
49.88
High
70.00
Current: 48.160
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Achieves Major Regulatory Milestone for Gene Therapy
- Stock Surge: uniQure's shares soared 78.4% on June 17 following the announcement of a major regulatory milestone for AMT-130, although a 3.9% drop on June 18 indicates some volatility; overall, investor confidence in the therapy appears to be strengthening.
- FDA Meeting Outcomes: During a recent Type B meeting, the FDA confirmed that three-year data from the AMT-130 study could serve as the primary basis for a Biologics License Application (BLA), which is expected to be filed in Q3 2026, potentially accelerating market access for the therapy.
- Clinical Trial Design Adjustments: The FDA has requested that uniQure align on the confirmatory study design before BLA submission, including the consideration of a standard-of-care control group, which will impact future clinical trial strategies and timelines.
- Significant Market Potential: As the first therapy for Huntington's disease to receive FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, AMT-130's potential approval could significantly enhance uniQure's market position, addressing a substantial unmet need in Huntington's disease treatment and presenting considerable commercial opportunities for the company.
See More
uniQure Releases Initial Data on Gene Therapy AMT-260
- Clinical Trial Progress: uniQure's Phase I/IIa trial of AMT-260 shows that three out of six patients achieved a 79% to 100% reduction in seizures over four to six months, indicating potential therapeutic efficacy for refractory mesial temporal lobe epilepsy.
- Safety Profile: As of the May 29, 2026 data cutoff, no serious adverse events were reported for AMT-260, with all adverse events classified as mild or moderate, primarily headaches (N=2), providing a solid safety foundation for future clinical applications.
- Ongoing Research Plans: Enrollment for a second higher-dose cohort is ongoing, expected to complete by mid-2026, with plans to present updated results in the first half of 2027, reflecting the company's continued confidence in the therapy's potential.
- Significant Market Potential: With approximately 300,000 refractory temporal lobe epilepsy patients in the U.S., the development of AMT-260 not only offers a new treatment option but also opens new market opportunities in the gene therapy sector, further solidifying uniQure's leadership in the industry.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bank of America reiterates Apple as a buy, believing that price increases are already reflected in the stock, anticipating that rising memory costs will force Apple to raise prices, impacting future earnings performance.
- Nice Upgrade: DA Davidson upgrades Nice from neutral to buy, maintaining a $110 price target, arguing that concerns about AI disruption are overblown, suggesting a more optimistic outlook that could boost the company's stock price.
- Immix Biopharma Initiation: Bank of America initiates coverage of Immix Biopharma with a buy rating and a $27 price target, citing the company's differentiated product offerings as a significant growth driver.
- Salesforce Upgrade: Monness Crespi Hardt upgrades Salesforce from neutral to buy with a $200 price target, based on its depressed valuation, strong cash flow generation, and support for customer transformation, which are expected to drive stock price increases.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
US Stocks Plunge as Tech Sector Weighs Down Market
- Market Weakness: On Wednesday, the S&P 500 Index fell by 1.21%, the Dow Jones Industrial Average dropped by 0.98%, and the Nasdaq 100 Index declined by 0.99%, reflecting market concerns over potential interest rate hikes by the Fed, particularly amid weak performance in technology stocks.
- Economic Data Support: Despite the market downturn, US May retail sales rose by 0.9% month-over-month, surpassing expectations of 0.6%, indicating resilient consumer demand, while pending home sales increased by 3.8% month-over-month, marking the largest gain in 20 months, potentially providing some support to the market.
- Fed Policy Outlook: The Fed maintained interest rates at its meeting on Wednesday but indicated through its dot plot that at least one more 25 basis point hike is expected this year, with the 2026 year-end federal funds rate projection raised to 3.75%, reflecting a cautious outlook on future economic conditions.
- International Market Response: While US stocks declined, overseas markets performed strongly, with the Euro Stoxx 50 reaching a new record high and closing up 0.68%, demonstrating global investor confidence in economic recovery, which may contrast with the US market's performance.
See More
uniQure's Gene Therapy AMT-130 Receives FDA Clearance
- Stock Surge: uniQure (QURE) shares soared over 70% during afternoon trading on Wednesday after the FDA cleared a regulatory path for its gene therapy candidate AMT-130, significantly boosting market confidence in the company.
- FDA Approval Pathway: The company announced plans to seek U.S. approval for AMT-130 in Q3 2026, targeting the rare neurodegenerative disorder Huntington's disease, highlighting the potential and market opportunity in this therapeutic area.
- Analyst Upgrade: Cantor Fitzgerald analyst Kristen Kluska upgraded uniQure's rating from Neutral to Overweight and raised the price target from $18 to $61 per share, reflecting an optimistic outlook on the company's future developments.
- Regulatory Meeting Impact: Although management has yet to receive the final minutes from the FDA meeting, analysts believe this update is material, indicating substantial progress in advancing AMT-130, which enhances investor confidence.
See More
uniQure Achieves Major Regulatory Milestone for Gene Therapy
- Stock Surge: uniQure's shares soared 78.4% on June 17 following the announcement of a major regulatory milestone for AMT-130, although a 3.9% drop on June 18 indicates some volatility; overall, investor confidence in the therapy appears to be strengthening.
- FDA Meeting Outcomes: During a recent Type B meeting, the FDA confirmed that three-year data from the AMT-130 study could serve as the primary basis for a Biologics License Application (BLA), which is expected to be filed in Q3 2026, potentially accelerating market access for the therapy.
- Clinical Trial Design Adjustments: The FDA has requested that uniQure align on the confirmatory study design before BLA submission, including the consideration of a standard-of-care control group, which will impact future clinical trial strategies and timelines.
- Significant Market Potential: As the first therapy for Huntington's disease to receive FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, AMT-130's potential approval could significantly enhance uniQure's market position, addressing a substantial unmet need in Huntington's disease treatment and presenting considerable commercial opportunities for the company.
See More
uniQure Releases Initial Data on Gene Therapy AMT-260
- Clinical Trial Progress: uniQure's Phase I/IIa trial of AMT-260 shows that three out of six patients achieved a 79% to 100% reduction in seizures over four to six months, indicating potential therapeutic efficacy for refractory mesial temporal lobe epilepsy.
- Safety Profile: As of the May 29, 2026 data cutoff, no serious adverse events were reported for AMT-260, with all adverse events classified as mild or moderate, primarily headaches (N=2), providing a solid safety foundation for future clinical applications.
- Ongoing Research Plans: Enrollment for a second higher-dose cohort is ongoing, expected to complete by mid-2026, with plans to present updated results in the first half of 2027, reflecting the company's continued confidence in the therapy's potential.
- Significant Market Potential: With approximately 300,000 refractory temporal lobe epilepsy patients in the U.S., the development of AMT-260 not only offers a new treatment option but also opens new market opportunities in the gene therapy sector, further solidifying uniQure's leadership in the industry.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bank of America reiterates Apple as a buy, believing that price increases are already reflected in the stock, anticipating that rising memory costs will force Apple to raise prices, impacting future earnings performance.
- Nice Upgrade: DA Davidson upgrades Nice from neutral to buy, maintaining a $110 price target, arguing that concerns about AI disruption are overblown, suggesting a more optimistic outlook that could boost the company's stock price.
- Immix Biopharma Initiation: Bank of America initiates coverage of Immix Biopharma with a buy rating and a $27 price target, citing the company's differentiated product offerings as a significant growth driver.
- Salesforce Upgrade: Monness Crespi Hardt upgrades Salesforce from neutral to buy with a $200 price target, based on its depressed valuation, strong cash flow generation, and support for customer transformation, which are expected to drive stock price increases.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
US Stocks Plunge as Tech Sector Weighs Down Market
- Market Weakness: On Wednesday, the S&P 500 Index fell by 1.21%, the Dow Jones Industrial Average dropped by 0.98%, and the Nasdaq 100 Index declined by 0.99%, reflecting market concerns over potential interest rate hikes by the Fed, particularly amid weak performance in technology stocks.
- Economic Data Support: Despite the market downturn, US May retail sales rose by 0.9% month-over-month, surpassing expectations of 0.6%, indicating resilient consumer demand, while pending home sales increased by 3.8% month-over-month, marking the largest gain in 20 months, potentially providing some support to the market.
- Fed Policy Outlook: The Fed maintained interest rates at its meeting on Wednesday but indicated through its dot plot that at least one more 25 basis point hike is expected this year, with the 2026 year-end federal funds rate projection raised to 3.75%, reflecting a cautious outlook on future economic conditions.
- International Market Response: While US stocks declined, overseas markets performed strongly, with the Euro Stoxx 50 reaching a new record high and closing up 0.68%, demonstrating global investor confidence in economic recovery, which may contrast with the US market's performance.
See More
uniQure's Gene Therapy AMT-130 Receives FDA Clearance
- Stock Surge: uniQure (QURE) shares soared over 70% during afternoon trading on Wednesday after the FDA cleared a regulatory path for its gene therapy candidate AMT-130, significantly boosting market confidence in the company.
- FDA Approval Pathway: The company announced plans to seek U.S. approval for AMT-130 in Q3 2026, targeting the rare neurodegenerative disorder Huntington's disease, highlighting the potential and market opportunity in this therapeutic area.
- Analyst Upgrade: Cantor Fitzgerald analyst Kristen Kluska upgraded uniQure's rating from Neutral to Overweight and raised the price target from $18 to $61 per share, reflecting an optimistic outlook on the company's future developments.
- Regulatory Meeting Impact: Although management has yet to receive the final minutes from the FDA meeting, analysts believe this update is material, indicating substantial progress in advancing AMT-130, which enhances investor confidence.
See More
